Not for direct or indirect publication or distribution within or in the United States of America, Australia, Canada, or Japan, or any other jurisdiction where such publication or distribution would be unlawful. Please note the important information at the end of this announcement.

‍

• Cantourage flower sales stable in its home market of Germany, but increasing price pressure in some market segments in the second half of 2025
• Foreign markets Poland and UK: Positive momentum continues; developing into key drivers for growth and profitability.
• CEO Philip Schetter returns to day-to-day operations after a brief personal leave of absence.‍

‍

‍Berlin, September 4, 2025 – Cantourage Group SE (“Cantourage,” ISIN: DE000A3DSV01, ticker: HIGH) continues to observe high demand for cannabis flowers in Germany. In some market segments, supply is also growing strongly, putting pressure on sales prices, which is also affecting Cantourage.

In this environment, Cantourage intends to focus on portfolio quality, selective, margin-sensitive growth, and strengthening international revenue streams. At the group level, revenue growth is still expected—with ambitious market expectations and challenging margin developments at the same time.

The debate initiated by the Federal Ministry of Health regarding restrictions on telemedical prescriptions and the shipment of cannabis flowers, which would make it more difficult for many patients in Germany to access tested and safe products, is causing additional uncertainty in the industry. The strategic steps now being taken are likely to increase the resilience of the cannabis flower business in Germany to possible changes in the law.

‍

Development in Germany: stable Cantourage sales, price-intensive market environment

Since cannabis was reclassified from a narcotic to a prescription drug on April 1, 2024, Cantourage has seen sustained solid demand for medical cannabis flowers, which has now stabilized at a high level. At the same time, increased imports and supply volumes from all market participants have put noticeable pressure on price levels compared to pharmacies. Cantourage intends to respond to this environment with clear measures:

• Active price and product range management
• Use of exclusivity for varieties in high demand
• Optimized purchasing conditions based on a broad network of cultivation partners established over many years with stable supply chains.

“After enormous growth following liberalization in 2024, the German market is now in a phase of readjustment: Demand is stable, but at the same time, the price pressure triggered by high supply is leading to a certain degree of uncertainty for the rest of the year,” says Cantourage CEO Philip Schetter, who returned to day-to-day business in August after a short personal break. “One thing is clear: our sales will continue to grow significantly in 2025. With the systematic expansion of our international business, which together with the active ingredient business in Germany already makes a substantial contribution to sales and earnings, we want to prepare Cantourage early on for possible market changes, especially in Germany,” Schetter continues.

Cantourage is closely monitoring the current regulatory debate surrounding restrictions on telemedical cannabis prescriptions and a possible restriction on mail-order pharmacies, and has taken initial precautions to be able to respond flexibly to possible changes. A statement from Cantourage on the current draft bill is available on the company's website (see “Further information”).

‍

Poland: Expansion of product range and recovery in demand

Demand for Cantourage products remains high in Poland. Another flower product has been successfully registered, with the first export to Poland scheduled for the fourth quarter of 2025. Further products are in the process of being registered, meaning that the Polish business is expected to make a significant contribution to the Group's results from 2026 at the latest.

The market background in Poland is also interesting: in the third quarter of 2024, restrictions on telemedicine, similar to those currently being considered by the Federal Ministry of Health, led to a decline in demand of over 50 percent, according to estimates by market participants. Despite the continuing restrictions on access to cannabis therapy, a significant recovery is expected in the course of 2025. Industry experts anticipate that the market will return to its pre-restriction level in the course of the coming year.

‍

United Kingdom: further expansion of business in a growing market environment

Cantourage UK is showing extremely solid business momentum in the current year. Based on current figures and plans, revenue growth of around 150 percent compared to the previous year is expected for 2025. The portfolio comprises over 30 active SKUs, with a total of more than 1.5 tons of cannabis flowers already delivered, generating revenue of several million euros.

‍

Active ingredient business: stable foundation

Cantourage's business with dronabinol and other active ingredients has been growing steadily for years and also makes a reliable contribution to earnings – in Germany as well as in Austria and Switzerland.

‍

Further information:

Statement by Cantourage Group SE on the draft bill by the Federal Ministry of Health to amend the Medical Cannabis Act:
www.cantourage.com/blog-posts/stellungnahme-der-cantourage-group-se-zum-referentenentwurf-des-bundesministeriums-fur-gesundheit-zur-anderung-des-medizinal-cannabisgesetzes

‍

About Cantourage
Cantourage is a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol, and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022, and is traded under the ticker symbol “HIGH.”

‍

Contact Investor Relations

ir@cantourage.com

‍

Press contact at Cantourage:
‍
Manuel Taverne| taverne@cantourage.com

‍

This announcement does not constitute a public offering or an advertisement for a public offering for the sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).